Elevai Labs (ELAB), subsidiary Elevai Biosciences, announced the next steps in its regulatory strategy for EL-22, aimed at treating obesity and preserving muscle mass. In collaboration with KCRN Research, the Company is preparing for a pre-IND meeting with the FDA, anticipated in the first quarter of 2025. This meeting will establish the development pathway for EL-22, clarifying any additional preclinical requirements and adjustments to Chemistry, Manufacturing, and Controls before IND submission.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.